New Gene Therapy Shows Promise for Alport Syndrome
Purespring Therapeutics plans an IND filing by 2027 after positive preclinical data indicates restored collagen production.
Updated on Oct. 27, 2026 in Biotech
Live Poll
Should more investment be directed toward developing gene therapies for rare genetic kidney diseases?
Purespring Therapeutics has presented preclinical data for PS-003, a gene therapy candidate designed to treat the underlying cause of X-linked Alport Syndrome. The company reported that the treatment restored collagen production in laboratory models, though the therapy remains in the research stage.
Why it matters
Alport Syndrome currently lacks approved treatments that address the root genetic defect of the disease. Purespring's development of a targeted gene delivery system aims to fill this clinical gap for patients suffering from progressive kidney failure.
The study analyzed 1.2 million genomes to identify 1,800 distinct pathogenic variants, while PS-003 preclinical tests demonstrated full-length COL4A5 gene expression in podocytes. These results contrast with existing supportive care measures that do not address the genetic origin of the condition.
The players
Purespring Therapeutics
A London-based biotechnology firm focused on developing gene therapies for kidney diseases using its proprietary podocyte-targeting platform.
The details
PS-003 utilizes the GlomThera platform, a specialized delivery system designed to target podocytes—highly specialized epithelial cells in the kidney's filtration barrier. By introducing a functional version of the COL4A5 gene, the therapy aims to enable these cells to resume the production of essential collagen. The preclinical research confirmed that this method produced full-length collagen proteins in human podocytes and maintained expression in murine models.
Timeline
October 27, 2026: Purespring presented preclinical data at ASN Kidney Week in Denver.
2027: Company plans to submit an Investigational New Drug application for PS-003.
The Tech Race
Purespring is competing in the emerging field of renal gene therapy, where the primary challenge is achieving precise delivery to filtration cells. This effort follows a broader industry trend of utilizing large-scale genomic datasets to better identify patient populations for rare disease interventions.
Patients and clinicians are currently in the research observation phase as the therapy has not yet entered human trials. Those interested in the condition can monitor future regulatory milestones or clinical trial enrollments once the IND application is submitted in 2027.
The takeaway
This candidate represents an attempt to move beyond current supportive care by targeting the genetic source of Alport Syndrome. Researchers and clinicians should track the upcoming 2027 IND submission to assess the transition from murine models to human clinical trials.
What happens next
Purespring Therapeutics plans to submit an Investigational New Drug (IND) application for the PS-003 gene therapy in 2027.
Further reading
Learn more about the latest developments in the Biotech sector.
Source note: This article includes information reported by The Manila times.
Live Poll
Should more investment be directed toward developing gene therapies for rare genetic kidney diseases?
